Phase-3 programs consisting of six or more trials are becoming increasingly commonplace. Yet another reason it requires so much R&D money, on average, to get one drug approved.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”